Dr Jack Yin Zheng, Chairman
Dr Jack Yin is the founder and Chairman of Trinity Innovation Bioventure Singapore Pte Ltd (TIBS). Prior to TIBS, Dr Yin was Managing Director of SDIC Fund Management Company where he led the investments of a number of companies, such as Dizal Pharma (spin-off with AstraZeneca R&D Shanghai), Ascentage Pharma (B06855.HK), CanSino (B06185.HK), Innovent (B01801.HK) and Brightgene (688166.SH).
Dr Yin has more than 20 years of in-depth biomedical industry experience. He attained his BSc and MSc at Nankai University and PhD at National University of Singapore. After his PhD graduation, Dr Yin worked with S*BIO and Novartis Institute for Tropical Diseases (Singapore), where he was responsible for drug discovery and development as well as project management.
Dr Zou Bin, CEO
Dr Zou Bin is the CEO of TIBS and an Adjunct Associate Professor at the National University of Singapore. Previously, Dr Zou Bin served as CSO at Aum Biosciences and CEO at Shanghai Blueray Biopharma, developing and managing competitive oncology pipelines. Prior to that, Dr Zou Bin was a Principal Investigator at Novartis Institute for Tropical Diseases (Singapore), where he invented the phase II antimalarial drug, NITD609.
Dr Zou Bin received his PhD from Prof. Dawei Ma (Shanghai Institute of Organic Chemistry) and postdoctoral training with Prof. K. C. Nicolaou (ICES, A*STAR).
Dr David Wang Xukun, Head of Investment
Dr Wang is the Head of Investment at TIBS. Dr Wang has more than 20 years of experience in biopharmaceutical industry covering a wide spectrum of Research & Development, Project Management, Business Development and Research Operations.
Prior to current position, he was the Alliance Management Director, Asia Pacific for Sanofi from 2014 to 2019 and Associate Director, Strategic Alliance and Outsourcing for Novartis from 2007-2014 (all based in Shanghai).
Dr Wang received his PhD and MBA degree from National University of Singapore and was also the recipient for ISPMB Gold Medal and Best Graduate Student. After graduation, he held scientific and managerial roles in local flagship biotech companies such as S*Bio and SingVax.